• Company also names Theodore Reiss EVP and Chief Medical Officer, and Jorg Thommes EVP, Pharmaceutical Sciences and Operations

CAMBRIDGE, Mass. – June 3, 2021 – Repertoire Immune Medicines, a clinical-stage biotech company decoding the immune synapse to create novel immune therapies for cancer, immune disorders, infectious disease and other serious diseases, today announced that Anne Walker has joined the company as Executive Vice President and Chief Financial Officer, effective June 7, 2021. She will report to CEO John Cox and serve on Repertoire’s executive committee.

Repertoire also announced the appointments of Theodore Reiss, MD, MBE, as Executive Vice President and Chief Medical Officer, and Jorg Thommes, PhD, as Executive Vice President, Pharmaceutical Sciences and Operations. The appointments of Anne, Ted and Jorg mark the expansion of Repertoire Immune Medicines’ leadership team.

“Anne’s deep experience across a wide range of strategic and financial planning disciplines will be invaluable to Repertoire as we execute transactions and research programs,” said John Cox. “The company has made great strides over the past year, and with the addition of Anne to the team, we’re poised for continued success and growth.”

Prior to joining Repertoire, Anne led Global Real Estate Services and Strategic Initiatives for Bank of America, where she was responsible for strategic investments in real estate and technology, as well as operational initiatives and company-wide efforts to drive responsible growth, including Operational Excellence and Capital and Scenario Planning Processes. Anne was the Bank of America New York City President, and served on the company’s management committee. Earlier in her career, she served as Managing Director and Head of the U.S. Equity Capital Markets Syndicate for Bank of America Merrill Lynch following Bank of America’s acquisition of Merrill Lynch in 2009, where she began her career in 1996. A graduate of Harvard University, Anne earned a Master of Business Administration degree from Columbia University.

As Executive Vice President and Chief Medical Officer, Ted is responsible for developing, accelerating and executing the company’s clinical development portfolio, and providing medical expertise in decisions affecting the company’s clinical development programs. He oversees Clinical Program Management, Clinical Research, Clinical Operations and Regulatory.

Ted was most recently a Venture Partner at Novo Ventures and previously at Celgene, where he led Clinical Research and Development, Inflammation and Immunology. He also has held global leadership positions in drug development at Novartis, Covance, and Merck. He has also served as Research Professor of Medicine at the Vanderbilt University School of Medicine. A graduate of the University of Pennsylvania, Ted earned his medical degree at Vanderbilt, and received a graduate degree in Bioethics from Penn.

As Executive Vice President, Pharmaceutical Sciences and Operations, Jorg will be responsible for developing Repertoire’s manufacturing, supply chain, and site infrastructure strategy. In this role, Technical Operations, and cGMP production will report to Jorg, and he will oversee Facilities & Security and Information Technology.

Jorg was most recently head of Chemistry, Manufacturing and Controls (CMC) at the Bill & Melinda Gates Medical Research Institute where he was responsible for end-to-end activities in CMC across the Institute’s portfolio of drugs, antibodies, vaccines, and related products. He spent more than 16 years at Biogen and its predecessor Idec Pharmaceuticals, with increasing responsibilities in technology and process development, technical operations and engineering, and ultimately as Senior Vice President of Engineering and Technology. He received undergraduate and doctoral degrees in Chemistry at the University of Bonn, Germany. He earned a post-doctoral degree in Biochemical Engineering (Habilitation) from the University of Dusseldorf, Germany.

About Repertoire Immune Medicines

Repertoire Immune Medicines is a fully integrated immune medicines company dedicated to creating treatments for serious diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens and regulate immune function. Repertoire’s strategy lies in understanding the immune synapse – the interaction between specific T cells and the corresponding antigen presenting cells that dictate T cell activity. The company’s proprietary DECODE™ technology platform, developed by Repertoire scientists, provides a unique understanding of the full repertoire of interactions between T cell receptors (TCRs) and their antigen targets. The ability to decode these interactions represents one of the greatest opportunities for innovation in medical science.

Repertoire’s team of more than 120 operates from sites in Cambridge, Massachusetts, and Zurich, Switzerland, using its DECODE technology to rationally design treatments for cancers, autoimmune disorders and infectious diseases. The company’s first product in the clinic, for metastatic solid tumors, is a novel multiclonal T cell therapy consisting of naïve, rare T cells derived from the peripheral blood, activated against a curated set of antigens, and armed with a proprietary cytokine payload. In the field of autoimmunity, Repertoire has discovered novel immune targets from patients with type 1 diabetes and other autoimmune diseases, providing the foundation for novel therapeutic candidates. The company is also using its DECODE platform to discover infectious disease antigens and responding T cell clones, providing the opportunity to develop targeted medicines for infectious diseases. To date, the company has raised more than $350 million from leading healthcare investors.

To learn more about Repertoire Immune Medicines, please visit our website: www.repertoire.com and follow us on LinkedIn and Twitter.